It has been reported that targeting B2M with a specific anti‐B2M antibody represents a potential novel therapeutic approach for the treatment of human renal cell carcinoma, prostate cancer, and hematological malignancies.15, 16, 17. This evidence concerns the gene B2M and prostate carcinoma.